Ex vivo–expanded tumor-infiltrating lymphocytes infused into lymphodepleted recipients has
clear antitumor efficacy. More practical sources of such antitumor lymphocytes would …

Adoptive T cell therapy is aimed at overcoming constraints of the endogenous immune
response. In patients with malignancies, this approach is based on the possibility of …

Therapy for non-Hodgkin lymphoma has benefited greatly from basic science and clinical
research such that chemotherapy and monoclonal antibody therapy have changed some …

OBJECTIVE: Active vaccination in the allogeneically reconstituted tumor-bearing host
essentially requires donor T–cell tolerance. To create a basis for vaccination in the …

The adoptive transfer of antigen-specific T cells has been used successfully to treat
experimental tumors in animal models and viral infections in humans, but harnessing the …

Graft-versus-tumor effects can be achieved after allogeneic bone marrow transplantation in
patients with malignancies of the kidney or hematopoietic system but are often accompanied …

Adoptive transfer of antigen-specific T lymphocytes is a powerful therapy for the treatment of
opportunistic disease and some virus-associated malignancies such as Epstein-Barr virus …

Antigen-specific tumor immunotherapy remains an attractive strategy for the treatment of
malignancies. In this review we will discuss why, despite the identification of large numbers …

The adoptive transfer of effector T cells combined with lymphodepletion has demonstrated
promising antitumor effects in mice and humans, although the availability of tumor-specific T …

The fate of tumor-specific CD4+ T cells is central to the outcome of the host immune
response to cancer. We show that tumor antigen recognition by a subset of CD4+ T cells led …